Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Celularity (CELU) EBITDA (2020 - 2025)

Celularity has reported EBITDA over the past 6 years, most recently at -$23.1 million for Q3 2025.

  • Quarterly results put EBITDA at -$23.1 million for Q3 2025, down 43.31% from a year ago — trailing twelve months through Sep 2025 was -$80.6 million (down 115.35% YoY), and the annual figure for FY2024 was -$57.9 million, up 70.48%.
  • EBITDA for Q3 2025 was -$23.1 million at Celularity, up from -$24.5 million in the prior quarter.
  • Over the last five years, EBITDA for CELU hit a ceiling of $49.9 million in Q3 2021 and a floor of -$93.9 million in Q3 2023.
  • Median EBITDA over the past 5 years was -$19.7 million (2025), compared with a mean of -$19.3 million.
  • Peak annual rise in EBITDA hit 1139.08% in 2021, while the deepest fall reached 29007.3% in 2021.
  • Celularity's EBITDA stood at -$4.0 million in 2021, then skyrocketed by 699.18% to $24.2 million in 2022, then tumbled by 70.45% to $7.2 million in 2023, then crashed by 285.91% to -$13.3 million in 2024, then crashed by 73.53% to -$23.1 million in 2025.
  • The last three reported values for EBITDA were -$23.1 million (Q3 2025), -$24.5 million (Q2 2025), and -$19.7 million (Q1 2025) per Business Quant data.